{"entity":{"id":"mirador-medsir","kind":"trial","name":"MiRaDoR","aka":["MIRADOR","MedOPP485"],"tldr":"A Spanish-led study that watches the blood of women with hormone-receptor-positive breast cancer and, if tumour DNA appears, tests newer hormone drugs to try to clear it.","summary":"MiRaDoR (NCT05708235, MedSIR) enrols 976 patients into ctDNA surveillance with a tumour-informed panel built from tumour and matched normal sequencing; only patients confirmed ctDNA-positive by the Signatera Genome test enter the treatment phase, where they receive giredestrant, giredestrant with abemaciclib, or, if their tumour carries a PIK3CA mutation on tissue, giredestrant with inavolisib. The primary endpoint is a decrease or clearance of ctDNA three months after starting treatment. The PIK3CA gate is read from the original tumour, not from what remains in the blood.","status":"active","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05708235","url":"https://clinicaltrials.gov/study/NCT05708235"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["mrd-testing"],"targets":["estrogen-receptor","pik3ca"],"drugs":["giredestrant","abemaciclib","inavolisib","signatera"],"companies":[],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05708235","phase":"2","setting":"HR-positive, HER2-negative early breast cancer at higher risk, operated on within five years: ctDNA surveillance, then treatment arms for patients who become ctDNA-positive (continued endocrine therapy, giredestrant, giredestrant plus abemaciclib, or giredestrant plus inavolisib for PIK3CA-mutated tumours)","sponsor":"MedSIR","started":"2024-04-01","startedType":"actual","enrolled":976,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/mirador-medsir/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/"},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}